General American Investors Co. Inc. bought a new position in shares of InMode Ltd. (NASDAQ:INMD - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 67,784 shares of the healthcare company's stock, valued at approximately $1,202,000. General American Investors Co. Inc. owned about 0.10% of InMode as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also recently modified their holdings of INMD. Atria Investments Inc grew its stake in shares of InMode by 23.1% during the fourth quarter. Atria Investments Inc now owns 15,088 shares of the healthcare company's stock worth $252,000 after buying an additional 2,828 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of InMode during the fourth quarter worth $1,332,000. PNC Financial Services Group Inc. grew its stake in shares of InMode by 17.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 21,208 shares of the healthcare company's stock worth $354,000 after buying an additional 3,193 shares during the last quarter. HighTower Advisors LLC bought a new stake in shares of InMode during the fourth quarter worth $180,000. Finally, Farther Finance Advisors LLC grew its stake in shares of InMode by 26.2% during the fourth quarter. Farther Finance Advisors LLC now owns 5,555 shares of the healthcare company's stock worth $93,000 after buying an additional 1,154 shares during the last quarter. Institutional investors own 68.04% of the company's stock.
Wall Street Analyst Weigh In
Several brokerages recently weighed in on INMD. UBS Group reduced their price objective on shares of InMode from $19.00 to $16.25 and set a "neutral" rating on the stock in a research note on Tuesday, April 29th. Jefferies Financial Group reduced their price objective on shares of InMode from $16.00 to $15.00 and set a "hold" rating on the stock in a research note on Monday, April 14th. Baird R W cut shares of InMode from a "strong-buy" rating to a "hold" rating in a research note on Monday, April 28th. BTIG Research lowered shares of InMode from a "buy" rating to a "neutral" rating in a report on Tuesday, April 29th. Finally, Canaccord Genuity Group restated a "hold" rating and issued a $15.00 target price on shares of InMode in a report on Friday, July 11th. Seven equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $18.54.
Check Out Our Latest Research Report on InMode
InMode Trading Down 1.4%
INMD stock traded down $0.20 during midday trading on Friday, hitting $13.90. The stock had a trading volume of 1,246,840 shares, compared to its average volume of 1,200,122. The firm has a market cap of $878.62 million, a P/E ratio of 5.97 and a beta of 1.95. InMode Ltd. has a 1-year low of $13.14 and a 1-year high of $19.85. The business has a fifty day moving average price of $14.40 and a two-hundred day moving average price of $16.14.
InMode (NASDAQ:INMD - Get Free Report) last released its earnings results on Monday, April 28th. The healthcare company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.14). InMode had a net margin of 44.79% and a return on equity of 17.17%. The firm had revenue of $77.87 million during the quarter, compared to analyst estimates of $82.21 million. During the same quarter in the previous year, the firm earned $0.32 EPS. InMode's quarterly revenue was down 3.0% on a year-over-year basis. On average, equities analysts anticipate that InMode Ltd. will post 1.75 EPS for the current year.
InMode Profile
(
Free Report)
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
Featured Articles
Before you consider InMode, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InMode wasn't on the list.
While InMode currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
